There are many faces of canine lymphoma, and outcomes and treatments are not all the same. This webinar covers when to use molecular diagnostic tests in those tricky cases, and how to manage the different versions of canine lymphoma appropriately for the best possible outcome.

So you have a diagnosis of lymphoma in your small animal patient. What next?  Classification of lymphoma is increasingly important for both prognostic and therapeutic decision making. This webinar will discuss diagnostic options to optimise the diagnostic process in your patient.  Modalities discussed will include immunocytochemistry, immunohistochemistry, flow cytometry and PARR. 

Tumors are quite frequent in companion animals, with malignant forms representing 56% of all the tumors in dogs and 80% in cats. Predicting the survival time and treatment response for malignant tumors is necessary to evaluate the best care options for the animal. Histological tumor grading helps veterinarians to define the prognosis, but each tumor has its own grading system with different prognosis, in terms of survival rate, metastatic rate, recurrence incidence. It could be not so easy to get your bearings in the pathologic words of gradings. The goal of this seminar is to be able to correlate the validated prognosis to each tumor grading we will see. We will rapidly review what tumor grading is and how it is evaluated. Then we will spend some time to review some of the most important tumor gradings (mammary tumors, mast cell tumors, melanomas, soft tissue sarcomas) and the correlated and validated prognostic factors. At the end of the seminar you will be able to clearly understand your pathologist’s report based on the grading system, and to use it to give an appropriate prognosis to the owners.